Equities Analysts Set Expectations for Alumis Q3 Earnings

Alumis Inc. (NASDAQ:ALMS) – Research analysts at HC Wainwright reduced their Q3 2026 EPS estimates for Alumis in a research note issued to investors on Friday, August 14th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.70) per share for the quarter, down from their previous estimate of ($0.69). HC Wainwright currently has a “Neutral” rating and a $25.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for Alumis’ Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.96) EPS, Q1 2027 earnings at ($0.74) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.76) EPS, Q4 2027 earnings at ($0.65) EPS and FY2027 earnings at ($2.91) EPS.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The firm had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.65 million.

A number of other analysts have also issued reports on ALMS. Citigroup reaffirmed a “neutral” rating on shares of Alumis in a research report on Monday. Wells Fargo & Company increased their price target on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Wall Street Zen lowered Alumis from a “sell” rating to a “strong sell” rating in a research note on Saturday. Morgan Stanley restated an “overweight” rating and set a $39.00 price objective on shares of Alumis in a report on Friday, May 15th. Finally, Guggenheim upped their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.30.

Alumis Price Performance

NASDAQ:ALMS opened at $25.50 on Tuesday. The firm has a 50-day moving average of $26.32 and a two-hundred day moving average of $25.26. The stock has a market cap of $3.25 billion, a P/E ratio of -6.61 and a beta of -0.69. Alumis has a 1-year low of $3.76 and a 1-year high of $31.35.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ALMS. KBC Group NV acquired a new position in shares of Alumis in the 1st quarter worth approximately $42,000. Strs Ohio raised its position in shares of Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after acquiring an additional 1,500 shares in the last quarter. State of Wyoming acquired a new stake in shares of Alumis during the 1st quarter valued at approximately $57,000. EverSource Wealth Advisors LLC lifted its stake in Alumis by 600.4% during the first quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock worth $69,000 after purchasing an additional 2,684 shares during the last quarter. Finally, Assetmark Inc. bought a new position in Alumis during the first quarter worth $92,000.

Insiders Place Their Bets

In related news, insider David M. Goldstein sold 2,596 shares of Alumis stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $68,456.52. Following the completion of the transaction, the insider directly owned 30,970 shares in the company, valued at approximately $816,678.90. This trade represents a 7.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sanam Pangali sold 1,364 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $35,968.68. Following the completion of the sale, the insider directly owned 9,747 shares of the company’s stock, valued at approximately $257,028.39. This represents a 12.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 19,953 shares of company stock worth $534,311. Company insiders own 33.70% of the company’s stock.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.